Becampanel

Becampanel

Clinical data
ATC code	None
Identifiers
IUPAC name ({[(2,3-Dihydroxy-7-nitro-5-quinoxalinyl)methyl]amino}methyl)phosphonic acid
CAS Number	188696-80-2
PubChem CID	5491960
ChemSpider	4590791
UNII	X3D0O800AJ
CompTox Dashboard (EPA)	DTXSID50172241
Chemical and physical data
Formula	C10H11N4O7P
Molar mass	330.193 g·mol−1
3D model (JSmol)	Interactive image
SMILES c1c(cc2c(c1CNCP(=O)(O)O)[nH]c(=O)c(=O)[nH]2)[N+](=O)[O-]
InChI InChI=1S/C10H11N4O7P/c15-9-10(16)13-8-5(3-11-4-22(19,20)21)1-6(14(17)18)2-7(8)12-9/h1-2,11H,3-4H2,(H,12,15)(H,13,16)(H2,19,20,21) Key:ABFMMCZFKUIJGQ-UHFFFAOYSA-N

Becampanel (INN; development code AMP397) is a quinoxalinedione derivative drug which acts as a competitive antagonist of the AMPA receptor (IC₅₀ = 11 nM). ^{[1] [2] [3] [4]} It was investigated as an anticonvulsant for the treatment of epilepsy by Novartis, and was also looked at as a potential treatment for neuropathic pain and cerebral ischemia, but never completed clinical trials. ^{[1] [2] [3] [5]}

References

1. Taylor JB, Triggle DJ (2007). Comprehensive medicinal chemistry II. Elsevier. p. 290. ISBN   978-0-08-044513-7.
2. Kwan P, Brodie MJ (September 2007). "Emerging drugs for epilepsy". Expert Opinion on Emerging Drugs. 12 (3): 407–422. doi:10.1517/14728214.12.3.407. PMID   17874969. S2CID   27627114.
3. Citraro R, Aiello R, Franco V, De Sarro G, Russo E (March 2014). "Targeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy". Expert Opinion on Therapeutic Targets. 18 (3): 319–334. doi:10.1517/14728222.2014.874416. PMID   24387310. S2CID   1504490.
4. World Health Organization (1988). International Nonproprietary Names (INN) for Pharmaceutical Substances. W.H.O. ISBN   9789240560369.
5. Pathan SA, Jain GK, Akhter S, Vohora D, Ahmad FJ, Khar RK (September 2010). "Insights into the novel three 'D's of epilepsy treatment: drugs, delivery systems and devices". Drug Discovery Today. 15 (17–18): 717–732. doi:10.1016/j.drudis.2010.06.014. PMID   20603226.